A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

NCT02982486 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER_GOV

Sponsor class

Conditions

Soft Tissue Sarcoma
Bone Sarcoma
Chondrosarcoma
Gastrointestinal Stromal Sarcoma
Ewing's Tumor Metastatic
Ewing's Tumor Recurrent
Osteosarcoma
Desmoplastic Small Round Cell Tumor

Interventions

DRUG: Ipilimumab
DRUG: Nivolumab

Sponsor

Assaf-Harofeh Medical Center